Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.61 and traded as high as $0.74. Xtant Medical shares last traded at $0.71, with a volume of 370,851 shares traded.
Xtant Medical Stock Performance
The company has a market cap of $99.41 million, a P/E ratio of -17.75 and a beta of -0.22. The company has a 50 day moving average price of $0.65 and a 200-day moving average price of $0.61. The company has a quick ratio of 1.16, a current ratio of 2.47 and a debt-to-equity ratio of 0.46.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of XTNT. Nantahala Capital Management LLC grew its stake in shares of Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company's stock worth $50,543,000 after purchasing an additional 57,000,000 shares in the last quarter. AWM Investment Company Inc. bought a new position in Xtant Medical during the second quarter valued at about $4,875,000. Crescent Grove Advisors LLC boosted its stake in Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company's stock valued at $304,000 after buying an additional 200,000 shares in the last quarter. Mink Brook Asset Management LLC boosted its stake in Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Xtant Medical during the second quarter valued at about $26,000. Institutional investors own 69.33% of the company's stock.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
